Creative Planning’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Creative Planning’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,514	Closed	-$266K	–	2036
2017 Q3	$266K	Sell	6,514 -230	-3%	-$7.22K	﹤0.01%	1404
2017 Q2	$203K	Buy	6,744 +54	+0.8%	+$1.69K	﹤0.01%	1511
2017 Q1	$242K	Buy	6,690 +2,000	+43%	+$88.2K	﹤0.01%	1378
2016 Q4	$235K	Sell	4,690 -158	-3%	-$8.3K	﹤0.01%	1327
2016 Q3	$254K	Sell	4,848 -24	-0.5%	-$1.15K	﹤0.01%	1274
2016 Q2	$201K	Sell	4,872 -425	-8%	-$18.5K	﹤0.01%	1253
2016 Q1	$215K	Buy	5,297 +768	+17%	+$26.4K	﹤0.01%	1174
2015 Q4	$188K	Hold	4,529	–	–	﹤0.01%	1238
2015 Q3	$70K	Buy	+4,529	New	+$97.3K	﹤0.01%	1815

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Creative Planning's FPRX Position: Q4 2017 in Review

Creative Planning sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 6,514 shares — an estimated $266K sold.

Creative Planning first reported a position in FPRX in Q3 2015 and held it in 9 quarters. The position peaked at $266K in Q3 2017. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

Creative Planning reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Creative Planning sold 6,514 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $266K.
Creative Planning first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
Creative Planning's Five Prime Therapeutics, Inc. position peaked at $266K in Q3 2017.
137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Creative Planning's 13F filing for Q4 2017, filed 17 Jan 2018.